Immobilized Peptide on the Surface of Core-shell LaVO4: Eu3@poly (levodopa) for Targeted Delivery of 5-Fluorouracil to Breast Tumor

Subject Areas : Journal of Animal Biology

Maryam Nazemian ¹ , Vida Hojati ² , Hamid Madanchi ³ , Hamid Hashemi-Moghaddam ⁴ , Saeed Zavareh ⁵ , Behrouz Johari ⁶

1 - Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
2 - Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
3 - Department of Medical Biotechnology, Faculty of Medicine, Semnan University of Medical Sciences, Iran|Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4 - Department of Chemistry, Damghan Branch, Islamic Azad University, Damghan, Iran
5 - Department of Biology, Damghan University, Damghan, Iran
6 - Department of Medical Biotechnology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

Received: 2020-08-03 Accepted : 2021-01-28 Published : 2023-02-20

Keywords: breast cancer, 5-Fluorouracil, Poly 3, 4-dihydroxy-l-phenylalanine, Anti-cancer peptide,

Abstract :

Chemotherapy using drug delivery systems can target tumor cells selectively and do not affect normal cells. In this study, a specific drug delivery system was designed with immobilized NL2 peptide on the surface of polymeric nano drug for breast tumor treatment. The tertiary structure of NL2 peptide (AEGEFIHNRYNRFFYWYGDPAK) was selected from the database and synthesized. After that, it was coupled to the synthesized poly-3,4-dihydroxy-1-phenylalanine (DOPA)/SiO2 nanocomposite and tested for targeted delivery of 5-fluorouracil (5-FU) to SK-BR3 breast cancer cell line and MCF-10A normal breast cell line. The results of MTT and hemolysis of red blood cells showed that the components of the nanocomposite and NL2 peptide do not have any cytotoxicity, while the results of the MTT test after washing showed that the nanocomposites functionalized with NL2 peptide had specificity for cells with Her2 marker, i.e. SK-BR3 cells, but after washing, they were separated from MCF-10A cells, which lack this marker, and the drug 5- Fluorouracil cannot exert its toxic effects on these cells. 

References:

1. Adams G.P., Weiner L.M. 2005. Monoclonal antibody therapy of cancer. Natural Biotechnology, 23(9):1147.


2. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. 2002. Therapeutic cancer targeting peptides. Peptide Science: Original Research on Biomolecules, 66(3):184-199.


3. Arap W., Pasqualini R., Ruoslahti E., 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279(5349):377-380.


4. Brahmbhatt H., MacDiarmid J. 2018. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells. (Google Patents, 2018).


5. Chilkoti A., Chen G., Stayton P.S., Hoffman A.S. 1994. Site-specific conjugation of a temperature-sensitive polymer to a genetically engineered protein. Bioconjugate Chemistry, 5(6):504-507.


6. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421(6924):756.


7. Das P., Jana N.R. 2015. Dopamine functionalized polymeric nanoparticle for targeted drug delivery. RSC Advances, 5(42):33586-33594.


8. Hashemi-Moghaddam H., Zavareh S., Mirsaeed Gazi E., Jamili M. 2018. Assessment of novel core–shell Fe3O4@ poly l‑DOPA nanoparticles for targeted Taxol® delivery to breast tumor in a mouse model. Materials Science and Engineering, C93:1036-1043.


9. Horning S.J., Younes A., Jain V., Kroll S., Lucas J., Podoloff D., Goris M. 2005. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Journal of Clinical Oncology, 23(4);712-719.


10. Http://crdd.osdd.net/raghava/tumorhope.


11. Jiang K., Schadler L.S., Siegel R.W., Zhang X., Zhang H., Terrones M. 2004. Protein immobilization on carbon nanotubes via a two-step process of diimide-activated amidation. Journal of Materials Chemistry, 14(1):37-39.


12. Zavareh S., Mahdi M., Erfanian S., Hashemi-Moghaddam H. 2016. Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma. Cancer Chemotherapy and Pharmacology, 78(5):1073-1084.